Cannabidiolic acid (CBDA) is a naturally occurring cannabinoid acid found in cannabis plants. It is the precursor to cannabidiol (CBD) and is produced through the enzymatic conversion of cannabigerolic acid (CBGA). CBDA is abundant in raw or unheated cannabis, and when it undergoes decarboxylation, converts into CBD.

Research on CBDA has shown promising potential in several areas. It exhibits anti-inflammatory properties and has been studied for its potential therapeutic applications in conditions such as arthritis and inflammatory bowel disease. CBDA also demonstrates potential antiemetic (anti-nausea and vomiting) effects, suggesting its usefulness in managing chemotherapy-induced nausea and vomiting. Additionally, early research indicates that CBDA may have anticonvulsant properties, making it a subject of interest in the treatment of epilepsy and seizure disorders.

While more research is needed to fully understand the pharmacological mechanisms and therapeutic potential of CBDA, ongoing studies continue to explore its various properties and applications. The conversion of CBDA to CBD upon decarboxylation highlights the importance of understanding the chemistry and pharmacology of cannabinoid acids in order to fully comprehend the effects and benefits of cannabinoids found in cannabis.